Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) have been given a consensus rating of “Hold” by the ten research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $25.20.
A number of equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. Wedbush reiterated an “outperform” rating and set a $12.00 price target (down previously from $17.00) on shares of Paratek Pharmaceuticals in a research note on Thursday, May 9th. HC Wainwright reiterated a “buy” rating on shares of Paratek Pharmaceuticals in a research note on Thursday, February 28th. LADENBURG THALM/SH SH set a $18.00 price target on shares of Paratek Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, February 28th. Finally, ValuEngine upgraded shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, April 1st.
Large investors have recently modified their holdings of the company. BNP Paribas Arbitrage SA acquired a new stake in shares of Paratek Pharmaceuticals in the 1st quarter valued at $36,000. Hsbc Holdings PLC acquired a new stake in shares of Paratek Pharmaceuticals in the 4th quarter valued at $59,000. Annex Advisory Services LLC boosted its stake in shares of Paratek Pharmaceuticals by 15.3% in the 4th quarter. Annex Advisory Services LLC now owns 15,100 shares of the specialty pharmaceutical company’s stock valued at $77,000 after purchasing an additional 2,000 shares in the last quarter. Stifel Financial Corp acquired a new stake in shares of Paratek Pharmaceuticals in the 4th quarter valued at $90,000. Finally, Raymond James Financial Services Advisors Inc. boosted its stake in shares of Paratek Pharmaceuticals by 15.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,867 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 2,500 shares in the last quarter. Institutional investors own 73.79% of the company’s stock.
PRTK opened at $4.18 on Thursday. Paratek Pharmaceuticals has a fifty-two week low of $4.02 and a fifty-two week high of $12.30. The company has a debt-to-equity ratio of 14.48, a quick ratio of 13.95 and a current ratio of 14.06. The firm has a market cap of $135.50 million, a price-to-earnings ratio of -1.17 and a beta of 1.52.
Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, May 8th. The specialty pharmaceutical company reported ($1.10) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.19) by $0.09. Paratek Pharmaceuticals had a negative net margin of 642.70% and a negative return on equity of 232.61%. The firm had revenue of $1.60 million for the quarter, compared to the consensus estimate of $0.89 million. On average, sell-side analysts anticipate that Paratek Pharmaceuticals will post -4.51 EPS for the current fiscal year.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.
Featured Article: What is a Reverse Stock Split?
Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.